Vimarsana
Biggest News Aggregation in the World

Ongoing Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ongoing Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ongoing Phase Today - Breaking & Trending Today

Evogene : Biomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma - Vimarsana News

Evogene : Biomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma

Published: May 23, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF...

Source: marketscreener.com
Related Topics:
United StatesElran HaberRachel Pomerantz GerberLavie BioGal MarkelYaron EldadCommission File NumberAmerican Society Of Clinical Oncology IncExchange CommissionEvogene LtdRabin Medical CenterAssociation For Clinical OncologyDavidoff Cancer CenterBiomica LtdSecurities ExchangeAmerican Society Of Clinical OncologyFile NumberFeinstein StreetPark RehovotForeign Private IssuerPresents Positive Clinical Data UpdateOngoing PhaseMicrobiome Based TherapeuticSecurities Exchange ActClinical Oncology
Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024 - Vimarsana News

Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024

Published: May 22, 2024

Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also Highlight the High Prevalence of Pre-Existing NS5A...

Source: marketscreener.com
Related Topics:
United StatesJean Pierre SommadossiJonae BarnesQi HuangAlina JucovAtea Pharmaceuticals IncGlobenewswire IncCorporate CommunicationsAtea PharmaceuticalsEuropean Association For The StudyWhile The CompanyInclude New Antiviral Efficacy ResultsLead In CohortOngoing PhaseAlso HighlightHigh PrevalenceResistance Associated SubstitutionsChief Executive OfficerEuropean TimeLead In Cohort Results FromWeek Combination RegimenChronic Hepatitisc VirusFavorable Antiviral ProfileHigh ResistanceLow Risk
Atea Pharmaceuticals Presents New Data Showcasing Potential Best-In-Class Combination Profile Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis... - Vimarsana News

Atea Pharmaceuticals Presents New Data Showcasing Potential Best-In-Class Combination Profile Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis...

Published: May 22, 2024

Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also H

Source: menafn.com
Related Topics:
United StatesAlina JucovQi HuangJonae BarnesJean Pierre SommadossiCorporate CommunicationsWhile The CompanyAtea PharmaceuticalsAtea Pharmaceuticals IncFounder Of Atea Pharmaceuticals WeInclude New Antiviral Efficacy ResultsLead In CohortOngoing PhaseAlso HighlightHigh PrevalenceResistance Associated SubstitutionsEuropean AssociationChief Executive OfficerEuropean TimeLead In Cohort Results FromWeek Combination RegimenChronic Hepatitisc VirusFavorable Antiviral ProfileHigh ResistanceLow Risk
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma - Vimarsana News

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

Published: April 26, 2024

$15 million CIRM Grant Supports the Ongoing Phase 1 TRAVERSE Trial Evaluating ALLO-316 in Patients with Advanced or Metastatic Renal Cell Carcinoma ALLO-316 Illustrates Proof-of-Concept in RCC and...

Source: marketscreener.com
Related Topics:
United StatesSouth San FranciscoChristine CassianoZachary RobertsResearch DevelopmentCalifornia Institute For Regenerative MedicineAllogene Therapeutics IncDrug AdministrationTechnology To Optimize Cart Cell ExpansionTherapeutics DevelopmentCorporate Affairs Brand StrategyAmerican Cancer SocietyOngoing PhaseMetastatic Renal Cell CarcinomaCell ExpansionCalifornia InstituteRegenerative MedicineExecutive Vice PresidentChief Medical OfficerChimeric Antigen ReceptorAbla CreaseyVice PresidentFast Track DesignationAllogene TherapeuticsForward Looking Statements
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - Vimarsana News

Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Published: April 1, 2024

– Continued active enrollment of Olvi-Vec in our pivotal Phase 3 OnPrime/GOG-3076 trial in platinum resistant/refractory ovarian cancer with topline results anticipated in 2H 2025 – ...

Source: marketscreener.com
Related Topics:
United StatesThomas ZindrickAnkit BhargavaGenelux CorporationSchool Of MedicineSecurities ExchangeExchange CommissionShanghai Jiao Tong UniversityAllele CommunicationsOngoing PhaseShanghai Chest HospitalGuggenheim SecuritiesYearly FinancialOn Prime PhaseSecurities ActSecurities Exchange ActPrivate Securities Litigation Reform ActShareholder Equity